Close
  Indian J Med Microbiol
 

Figure 1: ADA-EASD algorithm for antihyperglycemic therapy in type 2 diabetes[16]. ADA: American Diabetes Association, EASD: European Association for Study of Diabetes, HbA1c: Glycosylated haemoglobin, GI: Gastrointestinal, TZD: Thiazolidinedione, DPP-4 I: Dipeptidyl peptidase-4 inhibitor, GLP-1 RA: Glucagon like peptide-1 receptor agonist, MDI: Multiple daily injections, SU: Sulphonylurea. (a) Consider beginning at this stage in patients with very high HbA1c (e.g., ≥9%), (b) Consider rapid-acting, nonsulfonylurea secretagogues (meglitinides) in patients with irregular meal schedules or who develop late postprandial hypoglycemia on sulfonylureas, (c) additional potential adverse effects and risks may be seen, (d) Usually a basal insulin (NPH, glargine, detemir) in combination with noninsulin agents, (e) Certain noninsulin agents may be continued with insulin

Figure 1: ADA-EASD algorithm for antihyperglycemic therapy in type 2 diabetes<sup>[16]</sup>. ADA: American Diabetes Association, EASD: European Association for Study of Diabetes, HbA1c: Glycosylated haemoglobin, GI: Gastrointestinal, TZD: Thiazolidinedione, DPP-4 I: Dipeptidyl peptidase-4 inhibitor, GLP-1 RA: Glucagon like peptide-1 receptor agonist, MDI: Multiple daily injections, SU: Sulphonylurea. (a) Consider beginning at this stage in patients with very high HbA1c (e.g., ≥9%), (b) Consider rapid-acting, nonsulfonylurea secretagogues (meglitinides) in patients with irregular meal schedules or who develop late postprandial hypoglycemia on sulfonylureas, (c) additional potential adverse effects and risks may be seen, (d) Usually a basal insulin (NPH, glargine, detemir) in combination with noninsulin agents, (e) Certain noninsulin agents may be continued with insulin